Last Gasp Or New Life? 2009’s Novel Products Have Blockbuster Potential
Executive Summary
After a 2008 NME approval slate that was heavy on modest specialty products, the 2009 user fee calendar offers the potential for a return of the blockbuster
You may also be interested in...
ODAC To Assess Schering's PegIntron and GSK's Votrient In October
The committee will discuss PegIntron for melanoma, and Votrient for renal cell carcinoma.
Lilly, Daiichi Explore Pharmacogenomic Marker For Prasugrel
A May 4 Circulation article describing prasugrel's efficacy in patients who carry a genetic marker indicative of non-response to Plavix may be the opening volley in one of the first big marketing battles of the personalized medicine era
Lilly, Daiichi Explore Pharmacogenomic Marker For Prasugrel
A May 4 Circulation article describing prasugrel's efficacy in patients who carry a genetic marker indicative of non-response to Plavix may be the opening volley in one of the first big marketing battles of the personalized medicine era